Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clesacostat in NAFLD
NCT03248882Phase 2Completed
- Sponsor
- Pfizer
- Start
- Aug 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of clesacostat in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) (5 arms), sponsored by Pfizer. Primary endpoint: Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction at 16 weeks. Started Aug 2017; status: completed.
02
Drugs
clesacostat
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03248882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248882.